Interference with PD-L1 function by various experimental methods in tumor therapy has proven that immune checkpoint silencing may be a better strategy for strengthening therapeutic efficacy than immune checkpoint blocking [11,12,13,14,15,16,17]. The gene discussed is CD274; the disease is neoplasm.